Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program

Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Eloxx Pharmaceuticals (ELOX) in Focus: Stock Moves 6.9% Higher

WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx, will participate in a fireside chat and host one-on-one meetings with investors at the Piper Sandler 32 nd Annual Virtual Growth C onference. The fireside chat will be available on the Piper Sandler Conference website to registered attendees on November 23rd at 10:00 AM ET to December 3, 2020.

Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call Transcript

Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 202 1

Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update

A Publication titled: “ELX-02: an investigational read-through agent for the treatment of non sen se mutation-related genetic disease” has been published in the Expert Opinion on Investigational Drugs Journal

Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It's ERSG Library In Two Leading Journals

WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it presented data from two scientific abstracts at the North American Cystic Fibrosis Virtual Conference (NACFC). The two abstracts were also showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology . The live sessions and discussions will take place through October 23rd, 2020. These virtual posters are available to registered attendees on the NACFC online conference platform.

Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020

WALTHAM, Mass., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant. Dr. Kerem will continue to advise on our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities.

Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

WALTHAM, Mass., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts will be presented at the North American Cystic Fibrosis Conference (NACFC) to be held virtually starting on October 7, 2020. The two abstracts will be showcased in the NACFC virtual poster gallery and electronically published as a supplement to  Pediatric Pulmonology . These virtual posters will be available to registered attendees on the NACFC online conference platform starting on October 7, 2020.

Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference in October

WALTHAM, Mass., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has resumed at certain clinical sites in the U.S. after being temporarily paused in response to the COVID-19 pandemic. On June 17, 2020, we announced that enrollment had been resumed in the Phase 2 clinical trial in cystic fibrosis in Europe and Israel after a temporary pause due to the COVID-19 pandemic.

Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic

Eloxx Pharmaceuticals (ELOX) CEO Greg Williams on Q2 2020 Results - Earnings Call Transcript

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic

Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update

ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency

Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis

WALTHAM, Mass., July  28, 2020  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Dr. Gregory Williams, Chief Executive Officer of Eloxx, will make a presentation and host one-on-one meetings with investors at the 40th Annual Canaccord Genuity Virtual Growth C  onference  on August 13th, 2020.

Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020

Company management to host a webcast and conference call to provide a business update and review financial results at 2:00 p.m. ET Company management to host a webcast and conference call to provide a business update and review financial results at 2:00 p.m. ET

Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020

ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native stop codons ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native stop codons

Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics

Eloxx Pharmaceuticals (NASDAQ: ELOX) shares are trading higher on Thursday. The company announced that enrollment in its Phase 2 trial for ELX-02 has resumed in Israel and Europe.

Why Eloxx's Stock Is Trading Higher Today

WALTHAM, Mass., June  17, 2020  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has been resumed in Israel and Europe after being temporarily paused in response to the COVID-19 pandemic.

Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily in Response to the COVID-19 Pandemic

It was an overall good week for the market, but the flip to a bearish put-call ratio this morning tells us that there are plenty of volatile stocks poised for short-selling.

Eloxx Pharmaceuticals A Top Short After Recent 112 Percent Rally

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q1 2020 Results - Earnings Call Transcript

American States Water

BGC Partners

Ra Medical Systems Inc

SharpSpring

These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.

5 Stocks to Gain the Most With the Economy Set to Reopen

Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic

Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2019 Results - Earnings Call Transcript

Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020     Results from clinical and preclinical research to date support Company’s prioritization of Cystic Fibrosis programs     Headcount realignment to reduce operating expenses and significantly extend funding of operations through the end of 2021

News for Eloxx Pharmaceuticals Inc Stock (ELOX)